24 01, 2025

cfTAPS: a new method for cfDNA epigenomes

By | January 24th, 2025|Categories: ctDNA, Diagnostics Tech, Early detection, Epigenomics, Methods and applications, Next-generation sequencing|0 Comments

A new study introduces a sensitive and cost-effective method for MCED and diagnostic using multimodal cfTAPS, enhancing the potential of liquid biopsies. In this post I’ll take a dive into the new paper, lay out a short overview of DNAme-mod methods development, and the possible […]

13 01, 2025

Proteomics. Proteomics. Proteomics.

By | January 13th, 2025|Categories: ctDNA, Diagnostics Tech, Methods and applications, Next-generation sequencing, Other stuff|Tags: , |0 Comments

What does UK Biobank’s Pharma Proteomics election of Olink + Ultima Genomics NGS mean for proteomics researchers, and for the wider genomics community? Does it create a new Olink monopoly on NGS-proteommics? And what’s the impact on NGS technology providers? At the end of last […]

21 09, 2020

COVID diagnostics from @DNAnudge

By | September 21st, 2020|Categories: Diagnostics Tech, Methods and applications|0 Comments

A recent paper in The Lancet Microbe reports the first data from CovidNudge: DnaNudge’s rapid, lab-free COVID-19 test. The test: DnaNudge uses a SNP-genotyping technology developed by The Technology Partnership in Cambridge and explained in US10093965B2 patent. A sample is introduced into the Nudge cartridge, a disposable, sealed, and integrated lab-on-chip device,  […]

21 09, 2020

@illumina buys @GrailBio for $8 billion

By | September 21st, 2020|Categories: Diagnostics Tech, Early detection, Next-generation sequencing|1 Comment

Wow Illumina just spent $8 billion buying GRAIL; arguably the leader in methylation-based early detection of cancer with their Galleri test (read the press release). Get more info over at the website they’ve put together for the deal at transformingcancerdetection.com, which includes a presentation that also highlights […]

4 08, 2020

UK COVID diagnostics from @nanopore and @DNANudge

By | August 4th, 2020|Categories: Diagnostics Tech, Methods and applications, Nanopore sequencing, Next-generation sequencing|0 Comments

The UK biotech sector was in the news yesterday morning with two companies and their COVID tests making headlines: Oxford Nanopore and DNANudge. Both are offering rapid testing for COVID-19 in the NHS and in care homes (where they are desperately needed). There is only […]

23 06, 2020

Brain cancer testing without the invasive biopsy from @decarvalho_lab

By | June 23rd, 2020|Categories: Diagnostics Tech, Early detection, Epigenomics|0 Comments

Brain cancer is difficult to diagnose and stratify without an invasive biopsy. Daniel De Carvalho’s group have used their cfChIP-Seq technology to non-invasively diagnose and classify brain tumours, potentially removing the need for surgical tissue biopsies. The power of the assay comes from its use of […]

18 06, 2020

Tumour-informed sequencing to increase the sensitivity of ctDNA liquid biopsy

By | June 18th, 2020|Categories: ctDNA, Diagnostics Tech, MRD|0 Comments

A new paper from Nitzan Rosenfeld’s group at CRUK-CI (my old stomping ground) reports astounding sensitivity for ctDNA liquid biopsy. In “ctDNA monitoring using patient-specific sequencing and integration of variant reads” Jonathan Wan and his co-authors performed whole exome sequencing on tumour biopsies (and PBMCs) […]

5 06, 2020

Avida Biomed: early cancer detection with methylation

By | June 5th, 2020|Categories: Diagnostics Tech, Early detection, Epigenomics, MRD|0 Comments

Avida Biomed are an early startup who have developed a novel targeted methylation sequencing technology: Point-n-Seq, for cancer early-detection. Point-n-Seq uses targeted methylation sequencing, which performs enrichment of target molecules directly from cfDNA before bisulfite conversion and amplification. Target panels are small 1-1000 markers. The […]

Load More Posts